Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
clinical trials
deals
life sciences
national blog main
san francisco blog main
abbvie
allergan
alzheimer's disease
avapritinib
blueprint medicines
crispr
cstone pharmaceuticals
cynthia collins
editas medicine
eli lilly
european medicines agency
fda
fisogatinib
flatiron health
gene editing
genentech
hepatocellular carcinoma
investing
jeff albers
leber congenital amaurosis type 10
medullary thyroid cancer
michelle robertson
national top stories
non-small cell lung cancer
parkinson's disease
pralsetinib
rare diseases
roche
san francisco top stories
selpercatinib
thermo fisher scientific
What
medicines
pact
2
×
abbvie
alliance
approval
biotech
blueprint
cancer
candidate
currently
drug
editas
editing
exits
experimental
fda
gene
genetic
marketing
muscle
partnership
pruning
regulatory
research
ret
returning
review
rights
roche
team
terminated
treatment
wins
Language
unset
Current search:
pact
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact